

1103326-0624

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**OFFICIAL**

Applicants : Abrahamsson et al.
Serial No. : 09/581,967
Filed : June 19, 2000
For : ORAL FORMULATION FOR ILEUM ADMINISTERING
COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE ACID TRANSPORT
APR 21 2004
Examiner : Micah Paul Young
Group Art Unit : 1615

**RECEIVED
CENTRAL FAX CENTER**

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8	
I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date indicated below at the facsimile number 703-872-9306.	
Andrew Fessak	48,528
Agent Name	PTO Reg. No.
<i>Andrew Fessak</i>	<i>4/21/04</i>
Signature	Date of Signature

Date: April 21, 2004
Pages: 25 pages total
Facsimile: 1-703-872-9306

Group 1615
Assistant Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)(1)**

Sir:

Applicants submit this communication and the attached Form PTO/SB/08A. in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. A copy of each of the documents listed on the Form PTO/SB/08A is enclosed as part of this communication.

As part of this communication, Applicants are providing an English-language abstract of JP 04193836, published in the Japanese language and cited on Form PTO/SB/08A. Accordingly, Applicants are not providing a separate copy of JP 04193836.

OFFICIAL

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

**RECEIVED
CENTRAL FAX CENTER**

APR 21 2004

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the entry of the national stage as set forth in §1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last but before the mailing date of either:

- (1) a final action under §1.113 or
- (2) a notice of allowance under §1.311,

whichever occurs first.

STATEMENT OR FEE

Accompanying this Information Disclosure Statement is:

A. ☐ a statement as specified in 37 C.F.R. §1.97(e).

OR

B. ☒ the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$180.00).


METHOD OF PAYMENT OF FEE

- ☐ Attached is a check in the amount of \$ _____.
- ☒ Charge Account No. 23-1703 in the amount of \$ 180.00.

Authorization is given to the Assistant Commissioner to charge Deposit Account No. 23-703 for any additional fee which may be due in connection with this communication.

Dated: April 21, 2004

Respectfully submitted,



Andrew Fessak
Reg. No. 48,528
Agent for Applicants

Customer No. 007470
White & Case LLP
Direct Dial: (212) 819-3437

PTO/SB/08A (08-03)

Approved for use through 07/31/2006 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/511,967
		Filing Date	June 19, 2000
		First Named Inventor	Abrahamsson et al.
		Art Unit	1615
		Examiner Name	Micha Paul Young
Sheet	1	Attorney Docket Number	1103326-0624

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁵
		WO-02/32428 A1	04-25-2002	Starke et al.		
		JP 04193836	07-13-1992	Toshio		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
		A. Graul, J. Castaner, "Hypolipidemic HMG-CoA Reductase Inhibitor"; Drugs of the Future 1999; 24(5): pages 511-513.	

Examiner Signature

Date Considered

¹EXAMINER: Initial of reference cited, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of it is form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the publication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. ⁶Ap: item is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11. This collection is estimated to take 2 hours to complete, including searching, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.